Intech Investment Management LLC Acquires New Shares in Celcuity Inc. (NASDAQ:CELC)

Intech Investment Management LLC bought a new position in Celcuity Inc. (NASDAQ:CELC) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 16,649 shares of the company’s stock, valued at approximately $218,000.

Other hedge funds have also added to or reduced their stakes in the company. Bleakley Financial Group LLC bought a new position in shares of Celcuity in the fourth quarter valued at approximately $146,000. SG Americas Securities LLC boosted its holdings in Celcuity by 83.2% in the 4th quarter. SG Americas Securities LLC now owns 14,646 shares of the company’s stock valued at $192,000 after purchasing an additional 6,651 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in shares of Celcuity during the 3rd quarter valued at $205,000. XTX Topco Ltd bought a new position in shares of Celcuity in the third quarter worth $307,000. Finally, New York State Common Retirement Fund increased its holdings in shares of Celcuity by 14.9% in the fourth quarter. New York State Common Retirement Fund now owns 28,391 shares of the company’s stock worth $372,000 after purchasing an additional 3,682 shares during the period. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Analysts Set New Price Targets

Separately, Needham & Company LLC boosted their target price on Celcuity from $23.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, February 6th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Celcuity has a consensus rating of “Buy” and an average price target of $30.17.

Celcuity Stock Performance

NASDAQ CELC opened at $10.44 on Thursday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The company has a fifty day moving average of $11.22 and a 200-day moving average of $13.03. Celcuity Inc. has a 52-week low of $8.53 and a 52-week high of $22.19. The company has a market capitalization of $387.64 million, a P/E ratio of -4.00 and a beta of 0.65.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.